Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

1338801

USP

Indapamide

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C16H16ClN3O3S
Numéro CAS:
Poids moléculaire :
365.83
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

indapamide

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CC1Cc2ccccc2N1NC(=O)c3ccc(Cl)c(c3)S(N)(=O)=O

InChI

1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)

Clé InChI

NDDAHWYSQHTHNT-UHFFFAOYSA-N

Informations sur le gène

human ... SLC12A3(6559)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Indapamide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Indapamide Tablets

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazard

Mention d'avertissement

Warning

Mentions de danger

Classification des risques

Lact. - Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J J Mourad et al.
Current medical research and opinion, 25(9), 2271-2280 (2009-07-25)
Despite the widespread notion that controlling hypertension is essential to improve cardiovascular outcome, uncontrolled hypertension rates remain high. Fixed-dose combinations are used routinely to reduce the impact of hypertension. Treatment with fixed-combination perindopril/indapamide, for example, at the currently approved doses
P W de Leeuw
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 19(3), S41-S45 (2001-11-21)
Most patients with hypertension will need, at some stage, more than one drug to lower their blood pressure. Although monotherapy is still the preferred option for first-line treatment of hypertension, low-dose combination therapy as the initial medication has been increasingly
R Donnelly
Clinical pharmacokinetics, 37 Suppl 1, 21-32 (1999-09-24)
Recent international guidelines on the detection, clinical assessment and management of patients with hypertension have highlighted a number of themes that should be incorporated into routine clinical practice. First, although antihypertensive therapy is having a major impact on reducing the
Peter W de Leeuw
Expert opinion on pharmacotherapy, 12(11), 1827-1833 (2011-06-10)
Hypertension is an important risk factor for cardiovascular complications and the need to treat this condition has been well established. Despite the availability of many antihypertensive drugs, it is often necessary to combine several of these drugs. The compound perindopril/indapamide
Stéphane Laurent
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 21(3), S11-S18 (2003-08-22)
To review the safety and efficacy of the very-low-dose combination of perindopril 2 mg and indapamide 0.625 mg (Per2/Ind0.625) in essential hypertension, in relation to blood pressure control and target-organ damage. We included in this review several double-blind, randomized studies

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique